前田嘉信

Successful Extracorporeal Life Support for Life-threatening Hypercapnia with Bronchiolitis Obliterans after Allogeneic Hematopoietic Stem Cell Transplantation

JaLCDOI	10.18926/AMO/47266
フルテキストURL	65_6_403.pdf
著者	Waseda, Koichi\| Tanimoto, Yasushi\| Ichiba, Shingo\| Miyahara, Nobuaki\| Murakami, Toshi\| Ochi, Nobuaki\| Terado, Michihisa\| Nagano, Osamu\| Maeda, Yoshinobu\| Kanehiro, Arihiko\| Ujike, Yoshihito\| Tanimoto, Mitsune\|
抄録	Bronchiolitis obliterans (BO) is a disease with a poor prognosis, and a key factor that limits long-term survival after allogeneic hematopoietic stem cell transplantation (HSCT). We here report a case of a 31-year woman with acute lymphatic leukemia, which was treated by chemotherapy and HSCT, and consequently developed BO 2 years after HSCT. A non-tuberculous mycobacterial infection occurred and showed gradual exacerbation. She started taking anti-mycobacterial drugs, but lost appetite, felt tired and finally lost consciousness one month after beginning medication. Arterial blood gas revealed marked hypercapnia. Using extracorporeal life support (ECLS), the carbon dioxide concentration was reduced and her consciousness recovered. To our knowledge, this is the first case in which ECLS was successfully used for hypercapnia in a patient with BO.
キーワード	extracorporeal life support hypercapnia bronchiolitis obliterans noninvasive positive pressure ventilation
Amo Type	Case Report
出版物タイトル	Acta Medica Okayama
発行日	2011-12
巻	65巻
号	6号
出版者	Okayama University Medical School
開始ページ	403
終了ページ	406
ISSN	0386-300X
NCID	AA00508441
資料タイプ	学術雑誌論文
言語	英語
著作権者	CopyrightⒸ 2011 by Okayama University Medical School
論文のバージョン	publisher
査読	有り
PubMed ID	22189481
Web of Science KeyUT	000298516900007

Chronic Graft-versus-Host Disease: Disease Biology and Novel Therapeutic Strategies

JaLCDOI	10.18926/AMO/49251
フルテキストURL	67_1_1.pdf
著者	Nishimori, Hisakazu\| Maeda, Yoshinobu\| Tanimoto, Mitsune\|
抄録	Graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic stem cell transplantation. Chronic GVHD often presents with clinical manifestations that resemble those observed in autoimmune diseases. Standard treatment is 1-2mg/kg/day of prednisone or an equivalent dose of methylprednisolone, with continued administration of a calcineurin inhibitor for steroid sparing. However, the prognosis of steroid-refractory chronic GVHD remains poor. Classically, chronic GVHD was said to involve predominantly Th2 responses. We are now faced with a more complex picture, involving possible roles for thymic dysfunction, transforming growth factor-β (TGF-β) and platelet-derived growth factor (PDGF), B cells and autoantibodies, and Th1/Th2/Th17 cytokines, as well as regulatory T cells (Tregs), in chronic GVHD. More detailed research on the pathophysiology of chronic GVHD may facilitate the establishment of novel strategies for its prevention and treatment.
キーワード	chronic GVHD Th17 Am80 regulatory T cell (Treg) steroid-refractory
Amo Type	Review
出版物タイトル	Acta Medica Okayama
発行日	2013-02
巻	67巻
号	1号
出版者	Okayama University Medical School
開始ページ	1
終了ページ	8
ISSN	0386-300X
NCID	AA00508441
資料タイプ	学術雑誌論文
言語	英語
著作権者	CopyrightⒸ 2013 by Okayama University Medical School
論文のバージョン	publisher
査読	有り
PubMed ID	23439503
Web of Science KeyUT	000316829900001

Preparation of Enteric-coated Capsules of Beclomethasone Dipropionate for Patients with Intestinal Graft-versus-Host Disease and a Case Study

JaLCDOI	10.18926/AMO/51868
フルテキストURL	67_5_319.pdf
著者	Murakawa, Kiminaka\| Sato, Tomoaki\| Maeda, Yoshinobu\| Kitamura, Yoshihisa\| Tanimoto, Mitsune\| Sendo, Toshiaki\|
抄録	Graft-versus-host disease (GVHD) is a major concern in transplantation patients. Gut GVHD is accompanied by diarrhea, abdominal pain, and/or melena. Although oral treatment with corticosteroids (CSs) is effective in treating gut GVHD, it can cause adverse reactions that affect the entire body. Topical administration of CSs can be effective in treating diseases in which lesions are limited locally, because adverse reactions can then be alleviated. In this study, we examine and discuss an enteric-coated beclomethasone dipropionate (BDP) capsule (BDP-EC) formulated at Okayama University Hospital. The BDP-EC did not dissolve in solution 1 (pH1.2), and began disintegrating in solution 2 (pH6.8) after 5min, with a mean dissolution rate at 15min of 85%. We then used the capsule to treat a patient who developed gut GVHD after allogeneic hematopoietic stem cell transplantation. Clinically, the frequency of diarrhea decreased after BDP-EC administration. In addition, we were able to decrease the prednisolone equivalent dose. Symptoms associated with adverse reactions to BDP were not observed during the hospitalization period. These findings suggest that the administration of BDP-EC in the early stages of gut GVHD may allow a reduction in the initial doses of systemic CSs.
キーワード	beclomethasone intestinal graft-versus-host disease enteric-coated capsule in-hospital formulation
Amo Type	Case Report
出版物タイトル	Acta Medica Okayama
発行日	2013-10
巻	67巻
号	5号
出版者	Okayama University Medical School
開始ページ	319
終了ページ	324
ISSN	0386-300X
NCID	AA00508441
資料タイプ	学術雑誌論文
言語	英語
著作権者	CopyrightⒸ 2013 by Okayama University Medical School
論文のバージョン	publisher
査読	有り
PubMed ID	24145732
Web of Science KeyUT	000325836100006

An Open-labeled, Multicenter Phase II Study of Tamibarotene in Patients with Steroid-refractory Chronic Graft-versus-Host Disease

JaLCDOI	10.18926/AMO/54603
フルテキストURL	70_5_409.pdf
著者	Maeda, Yoshinobu\| Nishimori, Hisakazu\| Inamoto, Yoshihiro\| Nakamae, Hirohisa\| Sawa, Masashi\| Mori, Yasuo\| Ohashi, Kazuteru\| Fujiwara, Shin-ichiro\| Tanimoto, Mitsune\|
抄録	Chronic graft-versus-host disease (GVHD) is a major cause of late death and morbidity following allogeneic hematopoietic cell transplantation (HSCT). Retinoic acid (tamibarotene) exerts multiple effects on cell differentiation and is clinically used for the treatment of acute promyelocytic leukemia. Tamibarotene down-regulates both Th1 and Th17 differentiation in donor T cells after allogeneic HSCT, resulting in attenuation of experimental chronic GVHD. Based on preclinical data, we have launched a phase II study of tamibarotene in patients with steroid-refractory chronic GVHD. This study will clarify whether tamibarotene can exert beneficial effects in patients with steroid-refractory chronic GVHD.
キーワード	Am80 tamibarotene retinoid chronic GVHD steroid-refractory GVHD
Amo Type	Clinical Study Protocols
出版物タイトル	Acta Medica Okayama
発行日	2016-10
巻	70巻
号	5号
出版者	Okayama University Medical School
開始ページ	409
終了ページ	412
ISSN	0386-300X
NCID	AA00508441
資料タイプ	学術雑誌論文
言語	英語
著作権者	CopyrightⒸ 2016 by Okayama University Medical School
論文のバージョン	publisher
査読	有り
PubMed ID	27777437
Web of Science KeyUT	000388098700014

Anaplastic Lymphoma Kinase Fusion: A Review of Therapeutic Drugs and Treatment Strategies

JaLCDOI	10.18926/AMO/60796
フルテキストURL	74_5_371.pdf
著者	Makimoto, Go\| Ohashi, Kadoaki\| Maeda, Yoshinobu\| Kiura, Katsuyuki\|
抄録	The prognosis of advanced non-small cell lung cancer (NSCLC) patients has improved in recent decades, especially for patients with an oncogenic driver mutation. Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) are effective for patients with the echinoderm microtubule-associated protein-like 4-ALK fusion gene. Several ALK-TKIs have been established: the first-generation ALK-TKI, crizotinib; second-generation ALK-TKIs, alectinib and ceritinib; and third-generation ALK-TKI, lorlatinib. Some ALK-TKIs are effective for tumors that are resistant to other ALK-TKIs; however, as is known in epidermal growth factor receptormutant lung cancer, tumor resistance is inevitable. ALK-positive NSCLCs acquire resistance via various mechanisms, making it a heterogeneous disease. Therefore, it is necessary to develop next-generation treatment strategies, such as the use of next-generation ALK-TKIs for secondary mutations, or combination therapies with ALK-TKIs and other TKIs. In this review, we summarize the development and use of ALK-TKIs, prior pivotal clinical trials, and resistance mechanisms.
キーワード	lung cancer anaplastic lymphoma kinase tyrosine kinase inhibitors resistance mechanism
Amo Type	Review
出版物タイトル	Acta Medica Okayama
発行日	2020-10
巻	74巻
号	5号
出版者	Okayama University Medical School
開始ページ	371
終了ページ	379
ISSN	0386-300X
NCID	AA00508441
資料タイプ	学術雑誌論文
言語	英語
著作権者	CopyrightⒸ 2020 by Okayama University Medical School
論文のバージョン	publisher
査読	有り
PubMed ID	33106692
Web of Science KeyUT	000581970100001
NAID	120006892922

Rapid Disease Progression of Advanced Non-small Cell Lung Cancer Five Months after Cessation of Pembrolizumab

JaLCDOI	10.18926/AMO/60802
フルテキストURL	74_5_423.pdf
著者	Hirabae, Atsuko\| Ichihara, Eiki\| Sunami, Ryota\| Ota, Moeko\| Iwamoto, Yoshitaka\| Maeda, Yoshinobu\| Kiura, Katsuyuki\|
抄録	We report a case of late-onset hyperprogressive disease after cessation of a PD-1 inhibitor. A male was diagnosed with metastatic lung adenocarcinoma with little progression for 2 months before treatment. He received pembrolizumab as a second-line treatment and was subsequently prescribed docetaxel for 3 months until a slight increase in pleural effusion. At the time of progression to docetaxel, he commenced prednisolone because of immune-system-related diarrhea. After that, his general condition rapidly worsened with severe fatigue and hypoxia. Computed tomography revealed a massive increase of pleural effusion and replacement of almost the entire liver with cancer over a period of 5 weeks.
キーワード	lung cancer immune checkpoint inhibitors pembrolizumab hyperprogression
Amo Type	Case Report
出版物タイトル	Acta Medica Okayama
発行日	2020-10
巻	74巻
号	5号
出版者	Okayama University Medical School
開始ページ	423
終了ページ	425
ISSN	0386-300X
NCID	AA00508441
資料タイプ	学術雑誌論文
言語	英語
著作権者	CopyrightⒸ 2020 by Okayama University Medical School
論文のバージョン	publisher
査読	有り
PubMed ID	33106698
Web of Science KeyUT	000581970100007
NAID	120006892928

Volumetric PET Parameters Predict Prognosis after Definitive Chemoradiotherapy with Cisplatin/Docetaxel for Stage III Non-Small Cell Lung Cancer

JaLCDOI	10.18926/AMO/61429
フルテキストURL	75_1_15.pdf
著者	Katsui, Kuniaki\| Ogata, Takeshi\| Tada, Akihiro\| Sugiyama, Soichi\| Yoshio, Kotaro\| Kuroda, Masahiro\| Kiura, Katsuyuki\| Maeda, Yoshinobu\| Toyooka, Shinichi\| Hiraki, Takao\| Kanazawa, Susumu\|
抄録	The aim of this study was to investigate whether volumetric positron emission tomography (PET) parameters are prognostic predictors in stage III non-small cell lung cancer patients receiving definitive concurrent chemo-radiotherapy (CCRT) with cisplatin/docetaxel. Cases involving definitive CCRT were reviewed retrospectively, and the maximum standardized uptake value, metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were calculated. The relationships between these PET parameters and prognosis were analyzed. MTV and TLG were significant predictors of distant metastasis-free survival (DMFS) (p = 0.0003 and 0.0005, respectively) and progression-free survival (PFS) (p = 0.001 and 0.0007, respectively). The three-year DMFS rates in patients with low and high MTV were 13.3% and 64.6%, respectively, and the corresponding values in those with low and high TLG were 13.3% and 65.2%, respectively. The three-year PFS rates in patients with low and high MTV were 13.3% and 57.8%, respectively, and the corresponding values in patients with low and high TLG were 13.3% and 57.8%, respectively. However, MTV and TLG were not predictors of local control or overall sur-vival. We demonstrated that volumetric PET parameters were predictors of patients receiving definitive CCRT. Our findings contradict the findings of previous reports and warrant further research to validate them.
キーワード	volumetric positron emission tomography parameters distant metastasis-free survival chemoradiotherapy cisplatin/docetaxel non-small cell lung cancer
Amo Type	Original Article
出版物タイトル	Acta Medica Okayama
発行日	2021-02
巻	75巻
号	1号
出版者	Okayama University Medical School
開始ページ	15
終了ページ	23
ISSN	0386-300X
NCID	AA00508441
資料タイプ	学術雑誌論文
言語	英語
著作権者	CopyrightⒸ 2021 by Okayama University Medical School
論文のバージョン	publisher
査読	有り
PubMed ID	33649609

Successful Treatment of Acute Promyelocytic Leukemia Complicated with Endometrial Cancer by Arsenic Trioxide

JaLCDOI	10.18926/AMO/61904
フルテキストURL	75_2_219.pdf
著者	Sugiura, Hiroyuki\| Nishimori, Hisakazu\| Matsuoka, Hirofumi\| Nakamura, Keiichiro\| Fujii, Keiko\| Fujii, Nobuharu \| Matsuoka, Ken-ichi \| Maeda, Yoshinobu\|
抄録	Acute promyelocytic leukemia (APL) is a hematological emergency that requires urgent intervention because of the high incidence of early hemorrhagic death. When patients with APL experience a synchronous solid organ tumor, the tumor’s treatment must also be done properly. Differentiation-inducing therapy using arsenic trioxide (ATO) has less hematological toxicity compared to cytotoxic chemotherapy and might be preferable for untreated APL patients with a synchronous solid organ tumor. Here we describe the first successful case of untreated APL and synchronous endometrial cancer (in an adult Japanese woman) treated with ATO consolidation therapy and the subsequent surgery and chemotherapy for endometrial cancer.
キーワード	acute promyelocytic leukemia endometrial cancer arsenic trioxide synchronous multiple primary malignant tumor chemotherapy
Amo Type	Case Report
出版物タイトル	Acta Medica Okayama
発行日	2021-04
巻	75巻
号	2号
出版者	Okayama University Medical School
開始ページ	219
終了ページ	224
ISSN	0386-300X
NCID	AA00508441
資料タイプ	学術雑誌論文
言語	英語
著作権者	CopyrightⒸ 2021 by Okayama University Medical School
論文のバージョン	publisher
査読	有り
PubMed ID	33953429
NAID	120007029883

Monitoring of human herpesviruses after allogeneic peripheral blood stem cell transplantation and bone marrow transplantation

著者	前田嘉信\|
発行日	1999-06-30
出版物タイトル
資料タイプ	学位論文

Evaluation of an economic model composed of producer agents

著者	Itou Nao\| Maeda Yoshinobu\| Hayashi Toyohiko\|
発行日	2009-11-11
出版物タイトル	Proceedings : Fifth International Workshop on Computational Intelligence & Applications
巻	2009巻
号	1号
資料タイプ	会議発表論文

同種抗原による移植片対白血病効果減弱のメカニズム

著者	朝倉昇司\| 橋本大吾\| 高嶋秀一郎\| 杉山暖子\| 前田嘉信\| 赤司浩一\| 谷本光音\| 豊嶋崇徳\|
発行日	2012-04-01
出版物タイトル	岡山医学会雑誌
巻	124巻
号	1号
資料タイプ	学術雑誌論文

合成レチノイドAm80はTh1とTh17を抑制することにより慢性移植片対宿主病を改善する

著者	西森久和\| 前田嘉信\| 谷本光音\|
発行日	2012-12-03
出版物タイトル	岡山医学会雑誌
巻	124巻
号	3号
資料タイプ	学術雑誌論文

Progress of oral care and reduction of oral mucositis-a pilot study in a hematopoietic stem cell transplantation ward

著者	Soga, Yoshihiko\| Sugiura, Yuko\| Takahashi, Kanayo\| Nishimoto, Hitomi\| Maeda, Yoshinobu\| Tanimoto, Mitsune\| Takashiba, Shogo\|
発行日	2011-02
出版物タイトル	Supportive Care in Cancer
巻	19巻
号	2号
資料タイプ	学術雑誌論文

Febrile neutropenia and periodontitis: lessons from a case periodontal treatment in the intervals between chemotherapy cycles for leukemia reduced febrile neutropenia

著者	Soga, Yoshihiko\| Yamasuji, Yoshiko\| Kudo, Chieko\| Matsuura-Yoshimoto, Kaori\| Yamabe, Kokoro\| Sugiura, Yuko\| Maeda, Yoshinobu\| Ishimaru, Fumihiko\| Tanimoto, Mitsune\| Nishimura, Fusanori\| Takashiba, Shogo\|
発行日	2009-05
出版物タイトル	Supportive Care in Cancer
巻	17巻
号	5号
資料タイプ	学術雑誌論文

Oral mucositis in patients receiving reduced-intensity regimens for allogeneic hematopoietic cell transplantation: comparison with conventional regimen

著者	Takahashi, Kanayo\| Soga, Yoshihiko\| Murayama, Yumeno\| Udagawa, Mika\| Nishimoto, Hitomi\| Sugiura, Yuko\| Maeda, Yoshinobu\| Tanimoto, Mitsune\| Takashiba, Shogo\|
発行日	2010-01
出版物タイトル	Supportive Care in Cancer
巻	18巻
号	1号
資料タイプ	学術雑誌論文

Bacterial substitution of coagulase-negative staphylococci for streptococci on the oral mucosa after hematopoietic cell transplantation

著者	Soga, Yoshihiko\| Maeda, Yoshinobu\| Ishimaru, Fumihiko\| Tanimoto, Mitsune\| Maeda, Hiroshi\| Nishimura, Fusanori\| Takashiba, Shogo\|
発行日	2011-07
出版物タイトル	Supportive Care in Cancer
巻	19巻
号	7号
資料タイプ	学術雑誌論文

十二指腸濾胞性リンパ腫はAIDの発現を欠くがBACH2の発現を有しmemoryB細胞としての性質を有する

著者	高田尚良\| 佐藤康晴\| 中村直哉\| 徳中摩美\| 三木由香里\| 菊池イアーラ幸江\| 五十嵐和彦\| 伊藤悦郎\| 張替秀雄\| 加藤省一\| 林詠子\| 岡剛史\| 星井嘉信\| 田利晶\| 岡田裕之\| Mohamado, ABD Alkader Lamia\| 前田嘉信\| 谷本光音\| 木下朝博\| 吉野正\|
発行日	2013-08-01
出版物タイトル	岡山医学会雑誌
巻	125巻
号	2号
資料タイプ	学術雑誌論文

Distinct morphologic, phenotypic, and clinical-course characteristics of indolent peripheral T-cell lymphoma

著者	Hayashi, Eiko\| Takata, Katsuyoshi\| Sato, Yasuharu\| Tashiro, Yukie\| Tachiyama, Yoshiro\| Sawada-Kitamura, Seiko\| Hiramatsu, Yasushi\| Sugiguchi, Shun\| Nose, Soichiro\| Hirokawa, Mitsuyoshi\| Ando, Midori\| Abd Mader, Lamia\| Maeda, Yoshinobu\| Tanimoto, Mitsune\| Yoshino, Tadashi\|
発行日	2013-09
出版物タイトル	Human Pathology
巻	44巻
号	9号
資料タイプ	学術雑誌論文

移植後合併症の看護ポイント─GVHD③ 口腔GVHD

著者	杉浦裕子\| 曽我賢彦\| 前田嘉信\|
発行日	2010-09-01
出版物タイトル	造血細胞移植now&future
巻	20巻
資料タイプ	一般雑誌記事

白血病および白血病類縁疾患における分子標的治療

タイトル（別表記）	Molecular targeted therapies in leukemia
フルテキストURL	126_49.pdf
著者	前田嘉信\| 谷本光音\|
キーワード	白血病分子標的薬チロシンキナーゼ阻害薬
出版物タイトル	岡山医学会雑誌
発行日	2014-04-01
巻	126巻
号	1号
開始ページ	49
終了ページ	54
ISSN	0030-1558
関連URL	http://www.okayama-u.ac.jp/user/oma/
言語	日本語
著作権者	Copyright (c) 2014 岡山医学会
論文のバージョン	publisher
DOI	10.4044/joma.126.49

前田 嘉信